Cargando…

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm

Several studies have shown that thrombotic events may underlie a latent or subclinical myeloproliferative neoplasm (MPN) and precede its definite diagnosis by 1–2 years. An early diagnosis of patients with MPN, especially those with thrombotic events in the latent MPN phase, would be beneficial for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalala, Fani, Mamara, Antigoni, Ioannou, Maria, Speletas, Matthaios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401133/ https://www.ncbi.nlm.nih.gov/pubmed/22826794 http://dx.doi.org/10.4081/hr.2012.e12

Ejemplares similares

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report
por: Pemmaraju, Naveen, et al.
Publicado: (2012)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018)

Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
por: Shahrabi, Saeid, et al.
Publicado: (2018)

Erythrocyte-derived microvesicles induce arterial spasms in JAK2(V617F) myeloproliferative neoplasm
por: Poisson, Johanne, et al.
Publicado: (2020)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation
por: Sassi, Hela, et al.
Publicado: (2021)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients
por: Irino, Tamotsu, et al.
Publicado: (2011)

Improved Diagnosis of the Transition to JAK2 (V617F) Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms
por: Gonzalez, Mariana Selena, et al.
Publicado: (2014)

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
por: Bennemann, Karla, et al.
Publicado: (2012)

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
por: Deshpande, Anagha, et al.
Publicado: (2011)

Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms
por: Lee, Eunyoung, et al.
Publicado: (2018)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
por: Dagher, Tracy, et al.
Publicado: (2020)

Relationship of JAK2 (V617F) Allelic Burden with Clinico-Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms
por: Yow, Ka Shing, et al.
Publicado: (2020)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
por: Gou, Panhong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7e273jhm2ut991qk9r9ds9vjau